Etrasimod - Pfizer
Alternative Names: APD-334; Etrasimod arginine - Pfizer; PF-07915503; VELSIPITYLatest Information Update: 30 Aug 2024
At a glance
- Originator Arena Pharmaceuticals
- Developer Arena Pharmaceuticals; Everest Medicines; Pfizer
- Class 3-ring heterocyclic compounds; Acetic acids; Amino acids; Anti-inflammatories; Benzene derivatives; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Indoles; Skin disorder therapies; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ulcerative colitis
- Phase II/III Atopic dermatitis; Crohn's disease
- Phase II Eosinophilic oesophagitis
- Discontinued Alopecia areata; Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma gangrenosum
Most Recent Events
- 28 Aug 2024 Everest Medicines plans to launch Etrasimod (VELSIPITY®) in Hong Kong, in the second half of 2024
- 28 Aug 2024 Everest Medicines plans to launch Etrasimod (VELSIPITY®) in Macau, in the second half of 2024
- 28 Aug 2024 Everest Medicines plans to submit NDA for Etrasimod (VELSIPITY®) to China's NMPA for approval in the second half of 2024